Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Enclomiphene and Exemestane Interaction: Avoid | Peptide Database

Compound Profiles Enclomiphene Selective Estrogen Receptor Modulator | Testosterone & Fertility Support Enclomiphene competitively antagonizes estrogen receptors in the hypothalamus and anterior pituitary, blocking the negative feedback of estradiol on GnRH re

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

Enclomiphene

Selective Estrogen Receptor Modulator | Testosterone & Fertility Support

Enclomiphene competitively antagonizes estrogen receptors in the hypothalamus and anterior pituitary, blocking the negative feedback of estradiol on GnRH release. This disinhibition increases pulsatile GnRH secretion, which in turn stimulates the anterior pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

Exemestane

Steroidal Aromatase Inhibitor | Irreversible Estrogen Control

Exemestane functions as a mechanism-based (suicide) inhibitor of aromatase (cytochrome P450 19A1). Due to its steroidal structure, exemestane is recognized by aromatase as a substrate analogue and enters the enzyme's active site.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take Enclomiphene with Exemestane?

Combining Enclomiphene with Exemestane is not recommended. Both Enclomiphene and Exemestane carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is Enclomiphene and Exemestane safe together?

This combination carries significant risk. Both Enclomiphene and Exemestane carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between Enclomiphene and Exemestane?

Both Enclomiphene and Exemestane carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time Enclomiphene and Exemestane?

Enclomiphene has a half-life of ~10 hours and Exemestane has a half-life of ~24 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

What's the dose range for cognitive enhancement versus being too much?

The cognitive 'sweet spot' is 0.5-2 mg/kg body weight (roughly 35-140 mg for a 70 kg person). Doses above 2 mg/kg often shift from antioxidant to pro-oxidant effects, becoming counterproduc…

Source: peptide-db.com
comparison

BPC-157 vs TB-500: Mechanisms, Dosing & the Wolverine Stack

How BPC-157 and TB-500 compare for healing: mechanism differences, dosing protocols, clinical evidence, and when to combine both in the Wolverine Stack.

Source: peptide-db.com
comparison

Why is TB-500 dosed 2.5x higher in Tri-Heal Max versus standard Wolverine Stack?

Tri-Heal Max emphasizes TB-500's superior cell migration and angiogenesis properties (25mg vs standard 10mg) for more significant tissue damage. The 2.5:1 ratio targets acute injuries, majo…

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Community Research

Join others researching Cyclic Glycine-Proline — share findings, ask questions, and learn from real experiences Endogenous cyclic dipeptide found in plasma, breast milk, and cerebrospinal fluid. Functions as metabolite of IGF-1, regulating its bioavailability through competitive binding to IGFBP-3. Demonstrates neuroprotective, cognitive-enhancing, and cardioprotective properties supported by clinical trials. Competes with IGF-1 for IGFBP-3 binding, normalizing bioavailable IGF-1 levels. Acts as positive allosteric modulator of AMPA and GABA-A receptors. Increases BDNF levels via Akt/MDM2-p53 pathway activation.

Source: peptide-db.com ↗

Research Indications

Drostanolone propionate was FDA-approved for the treatment of advanced, inoperable breast cancer in postmenopausal women. Its anti-estrogenic properties provided tumor-suppressive effects in hormone-receptor-positive breast cancers. This indication has been superseded by modern selective estrogen receptor modulators and aromatase inhibitors, and pharmaceutical production has been discontinued. Masteron is primarily used during cutting phases and pre-contest preparation to achieve a hard, dry, and defined physique. Its anti-estrogenic and non-aromatizing properties eliminate water retention from the compound, while its androgenic effects promote muscle hardness and vascularity. Most effective when body fat is below 12-15%. At moderate doses alongside a testosterone base, Masteron can improve body composition by promoting a leaner, more vascular appearance without significant scale weight changes. Commonly used in recomposition phases where the goal is visual improvement rather than mass gain. Masteron's mild anti-estrogenic properties allow it to reduce circulating estradiol levels when stacked with aromatizable compounds like testosterone. Some users employ it specifically to minimize or eliminate the need for pharmaceutical aromatase inhibitors, which can negatively impact lipids, joint comfort, and bone mineral density.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

Raloxifene is administered orally as a tablet (raloxifene hydrochloride). It has approximately 60% oral absorption, though extensive first-pass glucuronidation results in an absolute bioavailability of about 2%. Despite the low bioavailability, the 60mg dose produces reliable clinical effects. Peak plasma concentrations are reached within 0.5-6 hours. The 28-hour half-life supports once-daily dosing. Can be taken with or without food. Gynecomastia reversal 60mg Once daily for 3-6 months Oral On-cycle gynecomastia prevention Once daily throughout cycle Osteoporosis prevention/treatment (medical) Once daily

Source: peptide-db.com ↗
Side effects

Common Side Effects

Diarrhea (more prevalent than with injectable GLP-1s) Nausea (typically improves after first month) Appetite reduction

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides

01
Peptide Therapy Guide Editorial Team

VIP Overview, Dosing & Safety | Peptide Database

VIP (Vasoactive Intestinal Polypeptide) Vasoactive Intestinal Peptide | Neuropeptide Community Research Join others researching VIP — share findings, ask questions, and learn from real experiences Vasoactive I…

Read guide →
03
Peptide Therapy Guide Editorial Team

Vilon Overview, Dosing & Safety | Peptide Database

Vilon (KE) KE Dipeptide | Thymus Immune Bioregulator Community Research Join others researching Vilon — share findings, ask questions, and learn from real experiences Vilon is a Khavinson bioregulator dipeptid…

Read guide →